UPCOMING WEBINAR SERIES
Platform Analytical Procedures, beyond the technical challenges
20 May 2026 | With experts from GSK
Join our experts, and by attending this webinar, you will:
- Gain a clear understanding of the regulatory environment for platform analytical procedures, including how ICH Q2 (R2) and Q14 extend beyond just technical aspects.
- Identify significant challenges and practical solutions for deploying and maintaining platform analytical procedures throughout different development and lifecycle stages.
- Evaluate the potential benefits and future influence of advanced platform strategies on efficiency, adaptability, and the overall analytical lifecycle in the industry.
Event Overview
This webinar will provide a practical definition of Platform Analytical Procedures and frame a discussion that extends beyond technical aspects. We will examine how ICH Q2 (R2) and Q14 contribute to platform methodologies, emphasising their benefits and how they facilitate streamlined, fit-for-purpose validation strategies. At the end, we will introduce a proposed documentation framework to ensure consistent and efficient implementation throughout the analytical lifecycle.
What you need to know:
Dual-time broadcast, with starting times as follows:
Wednesday, 20 May 2026
- Broadcast #1 (Europe/Asia): 10:00 h BST (London) / 11:00 h CEST (Paris/Berlin) / 14:30 h IST (New Delhi) / 17:00 h SGT (Singapore) / 18:00 h JST (Tokyo)
- Broadcast #2 (North America / Europe): 08:00 h PDT (Los Angeles) / 11:00 h EDT (New York) / 16:00 h BST (London) / 17:00 h CEST (Paris/Berlin)
Duration: Approximately 60 – 90 minutes, incl. Q&A.
Who should attend?
Anyone involved in method development, validation, and lifecycle management related to compliance, validation oversight, and the interpretation of evolving ICH guidelines, whether for practical application or regulatory compliance within biopharmaceutical analysis.
- Quality Control Scientists
- Analytical Development Scientists and Analytical Chemists
- CMC or Analytical Lifecycle Management Leads
- Quality Assurance (QA) professionals
- Regulatory Affairs and CMC Regulatory Specialists
- Technical or Scientific Managers, including Heads of Analytical Functions
Related events as part of the webinar series
Register now:
Presenters / Panellists
Jean-François Dierick, PhDStrategic Analytical Validation and Lifecycle LeadGSK (Belgium)Jean-Francois Dierick holds a PhD in Biology from the University of Namur (Belgium) in the field of cellular ageing proteomics, and a post-doc in proteomics from the University of Brussels (Belgium). Jean-Francois Dierick entered the pharmaceutical world at SGS, where he led the Biology Department (Biotechnology, Biochemistry, Cell Biology, Molecular Biology, Microbiology, Toxicology). In 2008, he joined GSK Vaccines, where he has held several positions in the analytics of biological products, both in development and in the commercial space. Today, he works at GSK as Strategic Analytical Validation and Lifecycle Lead / Vx Analytical R&D, leading the implementation of ICH Q2 and Q14.
Giovanni Vitali, MScQC Analytical Method Validation Senior Lead - Global QCGSK (Italy)
Jean-François Dierick, PhDStrategic Analytical Validation and Lifecycle LeadGSK (Belgium)Jean-Francois Dierick holds a PhD in Biology from the University of Namur (Belgium) in the field of cellular ageing proteomics, and a post-doc in proteomics from the University of Brussels (Belgium). Jean-Francois Dierick entered the pharmaceutical world at SGS, where he led the Biology Department (Biotechnology, Biochemistry, Cell Biology, Molecular Biology, Microbiology, Toxicology). In 2008, he joined GSK Vaccines, where he has held several positions in the analytics of biological products, both in development and in the commercial space. Today, he works at GSK as Strategic Analytical Validation and Lifecycle Lead / Vx Analytical R&D, leading the implementation of ICH Q2 and Q14.Giovanni Vitali, MScQC Analytical Method Validation Senior Lead - Global QCGSK (Italy)
| Presenters / Panellists |
|
Moderator
Dr. Ewoud van TrichtScientific DirectorBioQCExpert in (bio)pharmaceutical analysis with over 18 years of industrial experience in analytical development, Quality Control, and Analytical Quality by Design (AQbD). He has contributed to diverse therapeutic modalities, including small molecules, viruses, and cells, at leading companies such as Janssen Vaccines and Sanofi Cell Therapy.
Dr. Ewoud van TrichtScientific DirectorBioQCExpert in (bio)pharmaceutical analysis with over 18 years of industrial experience in analytical development, Quality Control, and Analytical Quality by Design (AQbD). He has contributed to diverse therapeutic modalities, including small molecules, viruses, and cells, at leading companies such as Janssen Vaccines and Sanofi Cell Therapy.
| Moderator |
|
Brought to you by:
